Share on StockTwits

Ovascience (NASDAQ:OVAS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Monday, AnalystRatings.Net reports.

A number of other analysts have also recently weighed in on OVAS. Analysts at Oppenheimer initiated coverage on shares of Ovascience in a research note on Tuesday, April 29th. They set an “outperform” rating and a $11.00 price target on the stock. Analysts at Leerink Swann raised their price target on shares of Ovascience to $16.00 in a research note on Thursday, April 3rd.

Ovascience (NASDAQ:OVAS) traded up 0.69% during mid-day trading on Monday, hitting $7.25. The stock had a trading volume of 46,325 shares. Ovascience has a 52-week low of $5.509 and a 52-week high of $16.00. The stock’s 50-day moving average is $8.39 and its 200-day moving average is $9.19. The company’s market cap is $169.3 million.

Ovascience (NASDAQ:OVAS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.41) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.46) by $0.05. Analysts expect that Ovascience will post $-1.95 EPS for the current fiscal year.

OvaScience, Inc, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.